Free Trial

Neurogene (NGNE) Competitors

Neurogene logo
$20.05 +0.30 (+1.49%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$20.00 -0.05 (-0.25%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NGNE vs. WVE, VERV, PAHC, AKBA, COLL, NTLA, PHVS, CRMD, RCUS, and SYRE

Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Pharvaris (PHVS), CorMedix (CRMD), Arcus Biosciences (RCUS), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

Neurogene vs. Its Competitors

Neurogene (NASDAQ:NGNE) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

In the previous week, Neurogene had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Neurogene and 2 mentions for WAVE Life Sciences. Neurogene's average media sentiment score of 0.15 beat WAVE Life Sciences' score of 0.00 indicating that Neurogene is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurogene
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neurogene has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 11.6% of Neurogene shares are held by company insiders. Comparatively, 29.1% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neurogene has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurogene$925K309.06-$75.14M-$4.35-4.61
WAVE Life Sciences$108.30M10.01-$97.01M-$0.84-8.30

Neurogene's return on equity of -36.16% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurogeneN/A -36.16% -32.51%
WAVE Life Sciences N/A -86.49%-37.20%

Neurogene currently has a consensus price target of $46.17, indicating a potential upside of 130.32%. WAVE Life Sciences has a consensus price target of $20.50, indicating a potential upside of 194.12%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurogene
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
WAVE Life Sciences
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92

Summary

Neurogene beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NGNE vs. The Competition

MetricNeurogeneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$285.88M$2.89B$5.49B$9.01B
Dividend YieldN/A2.43%5.38%4.09%
P/E Ratio-4.6121.5627.4220.26
Price / Sales309.06245.52407.97121.21
Price / CashN/A41.9536.6357.47
Price / Book0.967.518.085.67
Net Income-$75.14M-$55.05M$3.16B$248.47M
7 Day Performance24.04%4.59%2.81%3.29%
1 Month Performance-7.50%4.86%3.68%5.19%
1 Year Performance-44.29%5.82%35.29%21.35%

Neurogene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NGNE
Neurogene
3.828 of 5 stars
$20.05
+1.5%
$46.17
+130.3%
-44.3%$285.88M$925K-4.6190
WVE
WAVE Life Sciences
4.1705 of 5 stars
$6.96
+5.9%
$20.50
+194.5%
+31.0%$1.01B$108.30M-8.29240
VERV
Verve Therapeutics
3.4578 of 5 stars
$11.11
+0.5%
$14.75
+32.8%
+118.4%$985.92M$32.33M-5.27110High Trading Volume
PAHC
Phibro Animal Health
3.6755 of 5 stars
$24.46
+2.4%
$20.80
-15.0%
+63.3%$967.94M$1.02B31.361,940
AKBA
Akebia Therapeutics
4.3681 of 5 stars
$3.64
-1.1%
$6.75
+85.4%
+280.9%$966.50M$160.18M-17.33430Positive News
Insider Trade
COLL
Collegium Pharmaceutical
4.0432 of 5 stars
$29.88
+0.2%
$43.75
+46.4%
-6.1%$958.49M$631.45M24.49210
NTLA
Intellia Therapeutics
4.6508 of 5 stars
$9.23
+0.3%
$34.95
+278.7%
-53.3%$952.96M$57.88M-1.76600News Coverage
PHVS
Pharvaris
1.3657 of 5 stars
$17.42
-3.2%
$36.20
+107.8%
+10.4%$940.70MN/A-5.7930Gap Up
CRMD
CorMedix
2.6349 of 5 stars
$16.56
+21.7%
$15.83
-4.4%
+181.8%$923.09M$43.47M75.2830Analyst Revision
High Trading Volume
RCUS
Arcus Biosciences
2.911 of 5 stars
$8.65
+0.3%
$24.13
+179.1%
-41.1%$912.73M$258M-2.06500Positive News
SYRE
Spyre Therapeutics
1.586 of 5 stars
$14.68
-2.2%
$53.40
+263.8%
-38.5%$904.74M$890K-3.8973

Related Companies and Tools


This page (NASDAQ:NGNE) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners